Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 259

Results For "approval"

2604 News Found

Sputnik V needs to be priced at par with Covishield & Covaxin
News | April 23, 2021

Sputnik V needs to be priced at par with Covishield & Covaxin

Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply


PM urges vaccine manufacturers to scale production capacity
News | April 21, 2021

PM urges vaccine manufacturers to scale production capacity

The country has constantly worked with the spirit of public-private partnership


Glenmark Life Sciences files for IPO
News | April 18, 2021

Glenmark Life Sciences files for IPO

The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals


Pharma PLI to increase exports
Policy | April 14, 2021

Pharma PLI to increase exports

Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28


GlaxoSmithKline approves sale of Vemgal plant
News | April 05, 2021

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn


Lonza completes divestment of two sites to NextPharma
News | April 02, 2021

Lonza completes divestment of two sites to NextPharma

Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies


Promoters of Lincoln Pharma increases holding by 4.9%
News | April 01, 2021

Promoters of Lincoln Pharma increases holding by 4.9%

The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020


Biocon partners with Libbs to launch generic formulations in Brazil
Biotech | March 30, 2021

Biocon partners with Libbs to launch generic formulations in Brazil

Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market